The present invention relates to the selection of patients and treating the latter with carpipramine according to criteria relating to the property of carpipramine of preferentially blocking the alpha2C subtype, which can be used to characterize patients capable of benefiting from treatment with carpipramine, and to exclude those having disorders which cannot be improved by carpipramine.
展开▼